Overview
Vitalhub Q3 revenue up 94% yr/yr, beating analyst expectations
Adjusted EBITDA increased 58% yr/yr, representing 22% of revenue
Company focuses on integrating acquisitions and enhancing margins
Result Drivers
ACQUISITION GROWTH - ARR increase driven by acquisitions, contributing C$12 mln in Q3
PROJECT DELIVERIES - Completed project deliveries exceeded expectations, boosting services revenue
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
C$32 mln
C$28.40 mln (9 Analysts)
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Vitalhub Corp is C$15.00, about 31.9% above its November 5 closing price of C$10.22
The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 59 three months ago
Press Release: ID:nGNXPRkK4
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
